First Light Asset Management LLC decreased its stake in Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report) by 5.2% in the second quarter, Holdings Channel.com reports. The firm owned 3,023,256 shares of the company’s stock after selling 167,389 shares during the period. Amylyx Pharmaceuticals comprises about 3.3% of First Light Asset Management LLC’s holdings, making the stock its 10th biggest position. First Light Asset Management LLC’s holdings in Amylyx Pharmaceuticals were worth $54,298,000 at the end of the most recent reporting period.
Several other large investors have also recently modified their holdings of the stock. Meeder Asset Management Inc. bought a new stake in Amylyx Pharmaceuticals in the fourth quarter worth about $25,000. KBC Group NV bought a new stake in shares of Amylyx Pharmaceuticals during the 1st quarter worth approximately $26,000. California State Teachers Retirement System purchased a new position in Amylyx Pharmaceuticals during the 2nd quarter valued at $28,000. State of Wyoming bought a new stake in shares of Amylyx Pharmaceuticals during the second quarter worth $40,000. Finally, Caitong International Asset Management Co. Ltd grew its holdings in shares of Amylyx Pharmaceuticals by 954.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,859 shares of the company’s stock worth $47,000 after purchasing an additional 3,493 shares during the last quarter. Institutional investors own 95.84% of the company’s stock.
Insiders Place Their Bets
In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 15,000 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $18.32, for a total transaction of $274,800.00. Following the transaction, the insider directly owned 194,090 shares of the company’s stock, valued at $3,555,728.80. This trade represents a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 10.90% of the company’s stock.
Amylyx Pharmaceuticals Trading Down 4.4%
Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). On average, research analysts predict that Amylyx Pharmaceuticals, Inc. will post -1.48 earnings per share for the current fiscal year.
Analysts Set New Price Targets
AMLX has been the subject of several recent research reports. Guggenheim boosted their price target on shares of Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a “buy” rating in a report on Thursday, August 27th. Citigroup lifted their target price on shares of Amylyx Pharmaceuticals from $20.00 to $26.00 and gave the stock a “buy” rating in a research note on Monday, August 3rd. Robert W. Baird raised their price target on shares of Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the stock an “outperform” rating in a report on Wednesday, August 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Wednesday, August 5th. Finally, HC Wainwright raised their price objective on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $36.50.
Check Out Our Latest Stock Analysis on Amylyx Pharmaceuticals
About Amylyx Pharmaceuticals
Featured Articles
- Five stocks we like better than Amylyx Pharmaceuticals
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Want to see what other hedge funds are holding AMLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX – Free Report).
Receive News & Ratings for Amylyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amylyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
